OKYO Pharma logo

OKYO - OKYO Pharma News Story

8.5p -1.4  -13.9%

Last Trade - 12:35pm

Sector
Healthcare
Size
Small Cap
Market Cap £62.8m
Enterprise Value £62.7m
Revenue £n/a
Position in Universe 1086th / 1809

OKYO Pharma Limited - Result of General Meeting

Mon 20th May, 2019 10:58am
RNS Number : 5598Z
OKYO Pharma Limited
20 May 2019
 

20 May 2019

 

OKYO Pharma Limited

(Incorporated and registered in Guernsey with registered number 65220)
("OKYO" or the "Company")

 

Result of General Meeting, Admission of Subscription Shares and Total Voting Rights

 

Result of the General Meeting

 

The Company is pleased to announce that at the general meeting (the "General Meeting") held earlier today the proposed resolution set out in the notice of General Meeting dated 26 April 2019 was duly passed.

 

The number of votes 'for', 'against' and subject to the discretion of the chair of the General Meeting cast in relation to the resolution put before the General Meeting and the number of votes 'withheld' were as follows:

 

#

Description 

For


Against


Discretion


Total Votes

Withheld



No. of Votes

%

Votes Cast

No. of Votes

%

Votes Cast

No. of Votes

%

Votes Cast

No. of Votes (excluding Votes Withheld)

No. of Votes

1

Whitewash resolution

181,901

 

82.68

 

8,667

 

3.94

 

29,450

13.38

220,018

 

32,600

 


Notes:

- Votes 'withheld' are not counted in the calculation of the proportion of votes 'for' or 'against' a resolution.

- The total number of Ordinary Shares in issue as at the record time for the General Meeting was 524,108,283

 

Admission of Subscription Shares

 

Applications have been made to the Financial Conduct Authority (the "FCA") and the London Stock Exchange plc, respectively, for the admission of the 36,363,636 subscription shares (the "Subscription Shares") to the standard segment of the official list of the FCA and to trading on the main market of London Stock Exchange plc ("Admission").

 

It is expected that Admission will become effective and that dealings in the Subscription Shares will commence at 8:00 a.m. on 22 May 2019. The Subscription Shares will, on Admission, rank pari passu with the ordinary shares of no par value each in the capital of the Company (the "Ordinary Shares").

 

Total Voting Rights

 

Following Admission, the enlarged issued share capital will comprise 560,471,919 Ordinary Shares, with voting rights. This figure may be used by OKYO shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. The Company does not hold any Ordinary Shares in treasury.

 

End

 

Enquiries:

 

OKYO Pharma Limited

Willy Simon

 

+44 (0)20 7382 8300

Stockdale Securities Limited (Broker)

Andy Crossley

Antonio Bossi

David Coaten

 

+44 (0)20 7601 6100

For further information, please visit the Company's website at www.okyopharma.com.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ROMKBLBLKEFEBBQ
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.